(Q36548487)

14 August 2017

title

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (English)

1 reference

14 August 2017

1 reference

Kavitha Gopal

1

1 reference

14 August 2017

Timothy C Johnson

2

1 reference

14 August 2017

Saraswathi Gopal

3

1 reference

14 August 2017

Aaron Walfish

4

1 reference

14 August 2017

Christine T Bang

5

1 reference

14 August 2017

Pauline Suwandhi

6

1 reference

14 August 2017

Helene N Pena-Sahdala

7

1 reference

14 August 2017

David J Clain

8

1 reference

14 August 2017

Henry C Bodenheimer

9

1 reference

14 August 2017

Albert D Min

10

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

44

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

335-340

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

14 August 2017

cites work

1 reference

Host factors and failure of interferon-alpha treatment in hepatitis C virus

21 January 2018

1 reference

7 January 2021

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

1 reference

7 January 2021

Low density lipoprotein receptor as a candidate receptor for hepatitis C virus

1 reference

7 January 2021

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor

1 reference

7 January 2021

Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection

1 reference

7 January 2021

Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C

1 reference

7 January 2021

Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

7 January 2021

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA)

1 reference

7 January 2021

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

1 reference

7 January 2021

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

1 reference

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21261

1 reference

14 August 2017

1 reference